HIGHFDA DEVICE

Fujirebio Diagnostics Recalls Lumipulse ¿-Amyloid Controls Over Test Inaccuracy

Fujirebio Diagnostics recalled 179 units of Lumipulse ¿-Amyloid Plasma Controls on December 11, 2025. The recall stems from inaccurate test results leading to potential misclassification of Alzheimer's disease. Customers should stop using the device immediately and follow the manufacturer's instructions.

Official notice
Fujirebio DiagnosticsHealth & Personal CareMedical DevicesModel/Catalog Number: 81559UDI-DI: 05414470815593Lot Number: T8B6116U

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DEVICE
Recall date
December 11, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
December 11, 2025
Hazard Level
HIGH
Brand
Fujirebio Diagnostics
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Medical Devices; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Fujirebio Diagnostics
Product type
Quality Control Testing Device
Model numbers
Model/Catalog Number: 81559, UDI-DI: 05414470815593, Lot Number: T8B6116U
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    December 11, 2025

  2. Reported by FDA DEVICE

    February 11, 2026

  3. RecallRadar source check

    February 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an incorrect classification of a patient as having amyloid pathology associated with Alzheimer s disease (positive result) and/or requiring more clinical testing of that patient (indeterminate result).

What You Should Do

Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Fujirebio Diagnostics, Inc. or your healthcare provider for instructions. Notification method: Letter

About This Product

The Lumipulse ¿-Amyloid Plasma Controls are used as quality control in laboratories analyzing amyloid levels in plasma. They are essential for ensuring accurate test results in Alzheimer's disease diagnostics.

Why This Is Dangerous

The product may yield inaccurate results, causing patients to be misclassified regarding their Alzheimer's disease status. This can lead to unnecessary additional testing or incorrect treatment paths.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

The recall may lead to confusion and anxiety among patients awaiting test results, as well as potential delays in receiving appropriate care.

Practical Guidance

How to identify if yours is affected

  1. Check the model and catalog number on the product packaging.
  2. Verify if the lot number is T8B6116U.
  3. Consult any notification letters received from Fujirebio Diagnostics.

Where to find product info

Product model and lot numbers are typically found on the packaging or in the accompanying documentation.

What timeline to expect

Expect a refund or replacement processing time of approximately 4 to 8 weeks.

If the manufacturer is unresponsive

  • Document all communications with the company.
  • Reach out through alternative contact methods if no response is received.

How to prevent similar issues

  • Look for FDA-approved diagnostic tests in the future.
  • Verify that quality control products have clear labeling and regulatory approval.
  • Stay informed about recalls in the medical device industry.

Documentation advice

Keep copies of your purchase receipt, recall notification letters, and any correspondence with the manufacturer.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

The recalled product is Lumipulse ¿-Amyloid Plasma Controls, Model/Catalog Number 81559. The product contains Tris buffer with protein and chemical stabilizers, and it was sold nationwide in the U.S. between unspecified dates.

Key Facts

  • Recall date: December 11, 2025
  • Inaccurate test results may misclassify Alzheimer's disease
  • Contact Fujirebio for more instructions

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product TypeQuality Control Testing Device
Sold At
Multiple Retailers

Product Details

Model Numbers
Model/Catalog Number: 81559
UDI-DI: 05414470815593
Lot Number: T8B6116U
Affected States
ALL
Report Date
February 11, 2026
Recall Status
ACTIVE

Related Recalls